leisure time -WSS

leisure time

author：focus 2025-09-06 02:03:29 - browse：9952

Illustration of a road with a chasm in the middle, indicating the end of a deal or a problem with a deal — Adobe

A deal is never really done until it’s done.

On Tuesday, two different proposed insurance plan acquisitions on different sides of the country called it quits — one of them for the second time.

California-based Medicare Advantage insurer SCAN Group has been trying to buy CareOregon, an insurer offering coverage to half a million people in Oregon’s state health plan, since January 2023. National insurer Elevance has also been trying to buy Blue Cross and Blue Shield of Louisiana since last January. The on-again, off-again purchase was paused in September 2023 because of state regulators’ concerns, but was resubmitted with a slightly different plan in December.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Donor acceptance rates hint at racial, gender bias in heart transplants: study

knowledge

WSS

Decaf coffee targeted by food safety group under obscure FDA rule

Abortion pill case raises question: who can sue the FDA?

What will save rural psychiatry services? Higher Medicaid payments

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Focused ultrasound for uterine fibroids: an uphill battle

focus

leisure time

hotspot

Affirmative action in medical school literally saved lives

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Virginia high school admissions case could be legal follow

Health insurers say they are turning to AI to cut costs, improve care

Supreme Court strikes down use of affirmative action

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Apple is now the first public company to be valued at $3 trillion

Prosthetic arm enables patients to feel the objects they grip

explore

Oprah kicked off a national conversation on obesity. Let's have it

Why the world’s most expensive drug might be worth the price

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

There's no autism epidemic. It's an autism diagnosis epidemic

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

knowledge

knowledge

focus

focus